Inclusion Criteria:

        Patients must have:

          -  advanced solid tumors and have confirmed cMET dysregulation

          -  at least one measurable lesion as defined by RECIST 1.1.

          -  recovered from all toxicities related to prior anti-cancer therapies

          -  adequate organ function

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

        Patients must not have:

          -  known hypersensitivity to any of the excipients of INC280 or to benzodiazepines or
             known intolerance and hypersensitivity to caffeine

          -  symptomatic central nervous system (CNS) metastases who are neurologically unstable

          -  presence or history of carcinomatous meningitis

          -  history of another primary malignancy that is currently clinically significant or
             currently requires active intervention

          -  Clinically significant, uncontrolled heart diseases, including QTcF ≥ 450 ms (male
             patients), ≥ 460 ms (female patients) on the screening ECG

          -  Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280

          -  Major surgery within 4 weeks prior to starting INC280

          -  Patients receiving unstable or increasing doses of corticosteroids.

          -  Impairment of GI function or GI disease that may significantly alter the absorption of
             INC280

          -  Patients who have received or consumed, or are expected to receive or consume
             midazolam or caffeine-containing products (e.g., tea, coffee, cola), within 2 days
             prior to Day 1 and during the whole duration of the DDI phase (i.e., from Day -2 to
             Day 12)

        Other protocol-defined inclusion/exclusion criteria may apply